Arsenic Trioxide Affects the Proliferation of Gastric Cancer Cells through MiR-885-5p/CDC73 Axis

To explore Arsenic trioxide (As O ) and its regulated miR-885-5p/CDC73 signaling pathway involved in the development of gastric cancer. Fifty-two healthy patients and patients with gastric cancer were enrolled 2019-2020 in He Xian Memorial Hospital, Guangzhou, China. The patients with gastric cancer were divided into control group and As O administration group. After 2 courses of treatment, their peripheral blood was collected to analyze the therapeutic effect. miR-885-5p expression in peripheral blood was analyzed by qRT-PCR. As O was added into MGC-803 gastric cancer cell line at 0, 10, 20, 40 and 80 μmol/L. The proliferation rate and 48h IC50 value of gastric cancer cells were investigated by CCK-8, and the effect of As2O3 on miR-885-5p expression in the cells was analyzed. After 4 weeks of treatment, the objective efficiency of control group and As O administration group was 17.3% and 13.4%, respectively, without significant statistical difference. The overall benefit rate of As O administration group was significantly higher than that of the normal treatment group ( =0.049). qRT-PCR experiment results found that miR-885-5p significantly highly expressed in peripheral blood in the As O administration group, while miR-885-5p in gastric cancer was lower compared with normal people. Adding As O to the gastric cancer cells could significantly inhibit miR-885-5p expression, while miR-885-5p in gastric cancer cells affected cell expression by targeted regulation, affecting cell proliferation. As O may be used as a drug treatment program for gastric cancer, and mainly regulates the proliferation of gastric cancer cells by affecting the miR-885-5p/CDC73 target axis to participate in the development of gastric cancer.